epirubicin + trastuzumab

Epirubicin + trastuzumab is a combination therapy used primarily in the treatment of HER2-positive breast cancer. This combination pairs epirubicin, an anthracycline topoisomerase II inhibitor, with trastuzumab, a monoclonal antibody that targets HER2 receptors. The combination has shown promising efficacy in treating HER2-positive metastatic and early breast cancer, with studies demonstrating improved pathological complete response rates compared to non-concurrent regimens. However, this combination requires careful cardiac monitoring due to potential cardiotoxicity concerns when anthracyclines and trastuzumab are used together.